Genflow Biosciences reported interim six-month data from a randomized, blinded trial of SIRT6c gene therapy in 24 aged Beagles, comparing saline control, two intravenous plasmid DNA doses and an AAV8 benchmark. Treated dogs showed mean epigenetic age reductions on the Horvath dog clock of −1.08 years (low dose) and −0.48 years (high dose) versus −0.07 years in control, with 10 of 12 plasmid-treated animals below baseline, though no difference reached statistical significance. Tolerability was reported as favorable, with no treatment-related serious adverse events and no construct-related systemic inflammatory response.
Key Points
- Epigenetic age fell in treated dogs but not significantly
- Low plasmid dose outperformed high dose on methylation age
- Muscle histology showed preserved structure and activated regeneration
Longevity Analysis
Methylation clocks are being used as a decision-making endpoint in interventional trials rather than as retrospective correlates, and this study illustrates both the promise and the limits of that approach — a measurable directional shift in 10 of 12 treated animals that still fell short of statistical separation from control. The inverse dose relationship, with the lower plasmid dose producing the larger epigenetic shift, is a reminder that more aggressive intervention does not reliably translate to better downstream signaling. The parallel histological evidence of preserved muscle architecture and active regenerative capacity, alongside the absence of a systemic inflammatory response to the construct, matters as much as the clock reading: interventions that provoke immune activation or compromise tissue repair rarely survive translation regardless of their biomarker performance.
Original published by LT Wire.